tradingkey.logo

Ventyx Biosciences Announces Positive Data From Its Phase 2A Trial Evaluating Vtx3232 In Patients With Early-Stage Parkinson’S Disease

ReutersJun 17, 2025 11:39 AM

- Ventyx Biosciences Inc VTYX.O:

  • VENTYX BIOSCIENCES ANNOUNCES POSITIVE TOP-LINE DATA FROM ITS PHASE 2A SAFETY AND BIOMARKER TRIAL EVALUATING VTX3232 IN PATIENTS WITH EARLY-STAGE PARKINSON’S DISEASE

  • VENTYX BIOSCIENCES INC - VTX3232 STUDY MEETS PRIMARY GOAL OF SAFETY AND TOLERABILITY

  • VENTYX BIOSCIENCES INC - VTX3232 SHOWS SIGNIFICANT REDUCTIONS IN NLRP3-RELATED BIOMARKERS

  • VENTYX BIOSCIENCES INC - VTX3232 PHASE 2 TRIAL IN OBESITY AND CARDIOMETABOLIC RISK FACTORS RESULTS EXPECTED H2 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI